

## Fangzhou inks partnership to launch AI + Hepatitis prevention & control training centre in China

17 April 2025 | News

To focus on smart screening tools and Al-assisted treatment protocols

Fangzhou Inc., a leader in artificial intelligence (AI)-driven healthcare solutions in China, has partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area International Liver Disease Forum to launch the "AI + Hepatitis Prevention and Control Training Centre". This collaboration highlights the company's pioneering efforts in leveraging artificial intelligence for advanced liver disease management.

Dr Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, commented, "Our role in establishing this training centre highlights the company's technological excellence and commitment to social responsibility. By integrating our AI innovations with the Institute's clinical expertise, we aim to improve access to high-quality hepatology care. Fangzhou will focus on smart screening tools and AI-assisted treatment protocols to set new standards in liver disease prevention and management."

Fangzhou will continue to leverage AI as a core driver of innovation in the prevention and management of liver disease, while further enhancing standards for comprehensive full-cycle care. By deepening collaboration with research institutions, the company aims to accelerate Guangdong's efforts to mitigate the impact of viral hepatitis on public health.